Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Aura Biosciences, Inc. (NASDAQ: AURA), a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. These regulatory documents provide detailed insight into AURA’s financial condition, clinical development plans, governance, and capital markets activity.
Among the most frequently referenced filings are Aura’s Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, research and development focus on bel-sar (AU-011), and operating expenses tied to its global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, additional ocular oncology programs, and non-muscle invasive bladder cancer. Investors can also review Form 8-K current reports, such as those filed on dates when Aura announces quarterly results or updates its corporate presentation, to see how the company communicates material events and financial updates.
For users interested in ownership and governance, SEC filings provide information on matters submitted to stockholder votes, including director elections and auditor ratification, as illustrated by Aura’s Form 8-K reporting results of its annual meeting of stockholders. Registration statements and prospectus supplements related to public offerings of common stock and warrants detail how the company raises capital to fund its clinical programs and general corporate purposes.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly understand clinical priorities, cash runway disclosures, and risk factor discussions without reading every page. Real-time updates from EDGAR ensure new AURA filings appear promptly, while structured access to forms such as 10-K, 10-Q, 8-K, and registration statements allows investors to navigate Aura Biosciences’ regulatory history efficiently.
Form 4 overview: On 17 June 2025, Aura Biosciences (AURA) director Antony C. Mattessich reported equity-based awards that increase his direct ownership in the company.
- Restricted stock units: 13,000 RSUs were granted at no cost. The units convert 1-for-1 into common shares and vest in full on the earlier of 17 June 2026 or the next annual shareholder meeting, contingent on continued service.
- Stock options: 17,000 options with a US$6.18 exercise price were awarded on the same date. The options vest in full on the same schedule and expire 17 June 2035.
- Post-transaction holding: Mattessich now directly owns 23,500 common shares (includes previously held shares plus the new RSUs).
No open-market purchases or sales occurred; the filing reflects routine director equity compensation aligned with Aura’s 2021 Stock Option and Incentive Plan.
On 17 June 2025 Aura Biosciences, Inc. (Nasdaq: AURA) held its 2025 Annual Meeting of Stockholders, as reported in the Form 8-K filed 18 June 2025 under Item 5.07.
Participation: 38,863,371 common shares—or 77.3 % of the 50,268,758 shares entitled to vote—were present or represented by proxy.
Proposal 1 – Election of Class I Directors (terms through 2028)
- Elisabet de los Pinos, Ph.D.: 28,961,014 for; 985,262 withheld; 8,917,095 broker non-votes
- Giovanni Mariggi, Ph.D.: 29,179,073 for; 767,203 withheld; 8,917,095 broker non-votes
Both nominees were duly elected.
Proposal 2 – Ratification of Independent Auditor
- Ernst & Young LLP ratified for fiscal year ending 31 Dec 2025 with 38,623,566 for; 232,989 against; 6,816 abstentions; zero broker non-votes.
No additional matters were submitted. The filing contains no financial performance metrics, guidance, or transactional disclosures; therefore the event is considered routine corporate governance with limited immediate financial impact.